OTCMKTS:HLUYY H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis → The Next Nvidia? (From InvestorPlace) (Ad) Free HLUYY Stock Alerts $22.00 -0.01 (-0.02%) (As of 08/9/2022) Add Compare Share Share Today's Range$22.00▼$24.0050-Day Range$22.00▼$22.0052-Week Range$10.00▼$31.55Volume7,500 shsAverage Volume1,758 shsMarket Capitalization$21.91 billionP/E Ratio25.00Dividend Yield0.91%Price TargetN/A Stock AnalysisStock Analysis Get H. Lundbeck A/S alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.Read More HLUYY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLUYY Stock News HeadlinesApril 22, 2024 | msn.comNew Hampshire's 'Kid Conservationist' joins 'Jennifer Hudson Show' for Earth DayApril 18, 2024 | americanbankingnews.comH. Lundbeck A/S (OTCMKTS:HLUYY) Stock Price Passes Below Fifty Day Moving Average of $22.00April 25, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.April 16, 2024 | finance.yahoo.comH. Lundbeck A/S (LDBB.F)April 15, 2024 | msn.com‘Vanished’: 25 years since Nathan Edberg’s vehicle was found abandoned in Vadnais Heights, search for answers continuesMarch 25, 2024 | fool.comH. Lundbeck A/s (OTC: HLUYY)February 23, 2024 | investing.comH Lundbeck A/S ADR (HLUYY)February 11, 2024 | msn.comWWE: Becky Lynch gives fans a preview of what to expect from her bookApril 25, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.January 19, 2024 | msn.comA Chilling New Twist in the Lindbergh Baby Mystery Could Actually Flip the VerdictAugust 23, 2023 | wsj.comH. Lundbeck A/S Cl AAugust 11, 2023 | msn.com‘Finding W.H. Hudson’ Review: The Enigmatic BirdmanAugust 8, 2023 | nytimes.comTo Have and to Hold, Even if You Turn Into a Literal SharkJuly 18, 2023 | uk.investing.comH Lundbeck B (0ND5)May 12, 2023 | msn.comH. Lundbeck A/S reports Q1 resultsFebruary 8, 2023 | msn.comH. Lundbeck A/S reports FY resultsNovember 24, 2022 | finance.yahoo.comH. Lundbeck A/S (HLUN-B.CO)October 20, 2022 | investing.comH Lundbeck B (HLUNb)September 14, 2022 | msn.comMonica Lewinsky's Response to Death of Clinton Prosecutor Ken Starr PraisedSeptember 13, 2022 | msn.comWatch Lucid's Boss Spend an Hour Explaining How the Air's Motor WorksSeptember 9, 2022 | msn.comEveryone's Saying The Same Thing About Odell Beckham Jr. TonightSeptember 6, 2022 | msn.comSlain Memphis jogger Eliza Fletcher was a 2010 graduate of Baylor UniversitySeptember 3, 2022 | msn.comFormer Lutz Children’s Museum director busted on child pornography chargesSeptember 2, 2022 | yahoo.comFormer children’s museum director pleads guilty to child pornography chargesSeptember 2, 2022 | msn.comFormer executive director for Manchester children's museum pleads guilty to distributing child pornographySeptember 1, 2022 | news.yahoo.comFormer Lutz Children's Museum director admits distributing child pornAugust 31, 2022 | finance.yahoo.comRuben Östlund Remembers ‘Triangle of Sadness’ Actress Charlbi Dean: ‘A Shock and a Tragedy’See More Headlines Receive HLUYY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2015Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:HLUYY CUSIPN/A CIKN/A Webwww.lundbeck.com Phone(453) 630-1311Fax45-3630-1940Employees5,348Year Founded1915Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio25.00 Forward P/E Ratio10.48 P/E GrowthN/ANet Income$209.69 million Net Margins6.74% Pretax Margin7.83% Return on Equity13.74% Return on Assets7.16% Debt Debt-to-Equity Ratio0.32 Current Ratio1.15 Quick Ratio0.71 Sales & Book Value Annual Sales$2.59 billion Price / Sales8.45 Cash Flow$3.36 per share Price / Cash Flow6.54 Book Value$14.60 per share Price / Book1.51Miscellaneous Outstanding Shares995,741,000Free FloatN/AMarket Cap$21.91 billion OptionableNot Optionable Beta0.68 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Deborah Dunsire M.D. (Age 60)Pres & CEO Comp: $7.16MMr. Jacob Tolstrup (Age 50)Exec. VP of Commercial Operations & Chief Commercial Officer Comp: $888.17kMr. Lars Bang (Age 60)Exec. VP of Product Devel. & Supply Comp: $915.5kDr. Per Johan Luthman (Age 63)Exec. VP of R&D Comp: $901.84kMr. Bjorn R. MogensenSr. VP Group Fin.Dr. Tarek Samad Ph.D.Sr. VP & Head of ResearchMr. Palle Holm OlesenChief Specialist & VP of Investor RelationsMs. Elise Hauge (Age 55)Exec. VP of People & Communication Mr. Ole Chrintz (Age 64)Sr. VP of International Markets Mr. Keld Flintholm Jorgensen (Age 51)Exec. VP of Corp. Strategy & Bus. Devel. More ExecutivesKey CompetitorsEisaiOTCMKTS:ESALYShionogi & Co., Ltd.OTCMKTS:SGIOYSandoz GroupOTCMKTS:SDZNYEurofins ScientificOTCMKTS:ERFSFSysmexOTCMKTS:SSMXYView All Competitors Should I Buy H. Lundbeck A/S Stock? HLUYY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in H. Lundbeck A/S: H. Lundbeck A/S has a diverse portfolio of pharmaceutical products targeting psychiatric and neurological disorders, providing a wide range of revenue streams. The company's recent partnership agreements and collaborations indicate a focus on innovation and potential for future growth. With the introduction of Vyepti for migraine prevention, H. Lundbeck A/S has expanded its product offerings into a high-demand therapeutic area. Investors may find the company's focus on real-world evidence in support of migraine therapy promising for market differentiation and potential market share growth. Current stock price of HLUYY is showing a positive trend, indicating potential value appreciation for investors. Cons Investors should be bearish about investing in H. Lundbeck A/S for these reasons: The competitive landscape in the pharmaceutical industry can pose challenges for market share and pricing pressures. Regulatory uncertainties and changes in healthcare policies could impact the company's product development and market access. Dependency on a few key products for a significant portion of revenue may expose the company to risks associated with product lifecycle and patent expirations. Fluctuations in currency exchange rates can affect the company's financial performance, especially in international markets. Market volatility and macroeconomic factors may influence investor sentiment towards the company's stock. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these H. Lundbeck A/S pros and cons to contact@marketbeat.com. HLUYY Stock Analysis - Frequently Asked Questions Should I buy or sell H. Lundbeck A/S stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" HLUYY shares. View HLUYY analyst ratings or view top-rated stocks. How have HLUYY shares performed in 2024? H. Lundbeck A/S's stock was trading at $22.00 at the beginning of the year. Since then, HLUYY stock has increased by 0.0% and is now trading at $22.00. View the best growth stocks for 2024 here. How were H. Lundbeck A/S's earnings last quarter? H. Lundbeck A/S (OTCMKTS:HLUYY) posted its quarterly earnings data on Wednesday, November, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The business had revenue of $547.05 million for the quarter, compared to analyst estimates of $514.82 million. H. Lundbeck A/S had a net margin of 6.74% and a trailing twelve-month return on equity of 13.74%. Is H. Lundbeck A/S a good dividend stock? H. Lundbeck A/S (OTCMKTS:HLUYY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.91%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLUYY will have a dividend payout ratio of 7.02% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for HLUYY. How do I buy shares of H. Lundbeck A/S? Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does H. Lundbeck A/S have any subsidiaries? The following companies are subsidiares of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.Read More This page (OTCMKTS:HLUYY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H. Lundbeck A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.